• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

3v.org

Venture Capital Matters

  • Sponsored Post
    • Make a Contribution
  • Market Reports
  • Technologies
    • Technology Events
    • Startup Jobs
  • Domain Names for Startups
  • About
    • How to raise venture capital
    • How to raise seed funding from angel investors
    • How private equity and venture capital firms operate
    • What is the difference between private equity and VC funding?
    • What technology trends are considered hot among VC firms?
    • What is elevator pitch?
    • What is startup burn rate?
    • Does failure to launch a startup spell the end of the entrepreneur’s ambitions?
    • How to avoid pitfalls in founding a startup
    • Why do startups fail?
    • What are the traits of successful startup founder?
    • What are startup vanity metrics?
    • Why investing in the next generation of women and diverse entrepreneurs is a crucial part to the success of the tech infrastructure
    • Where are VCs seeing opportunity
    • How do startup valuations work?
    • What is startup accelerator?
    • How to scale an early-stage startup team, how much to pay and how to distribute equity
    • Don’t mix business with friendship: when it comes to building a founding team for a startup, this adage may not always apply
    • What is a social unicorn?
    • Secure Your Startup’s Future: The Importance of Succession Planning
  • Contact

Livionex Pharma Raises $4 Million Series A at a $180 Million Valuation to Address Unmet Medical Needs in Periodontitis, Cataracts and Herpes Simplex Virus

May 13, 2019 By admin Leave a Comment

What if one biotech company could potentially prevent and treat prevalent diseases, such as gingivitis, periodontitis, cataracts, and herpes simplex virus? Today, Livionex emerges out of stealth with 2 major announcements:

The closing of an oversubscribed $4 million Series A round at a $180 million valuation from select private investors and family offices.
The launch of the Company’s new and improved oral care line, LIVFRESH (www.getlivfresh.com) as a dentist-recommended, clinically proven solution for eliminating plaque.
The funding will be used to accelerate the growth of their technology that is advancing treatments for gum disease, cataracts, and herpes simplex virus.

Oral Care
Using safe, edible ingredients on the FDA’s GRAS list, LIVFRESH Dental Gel has been clinically proven to remove plaque 250% better than a market leading toothpaste and is currently being evaluated by the FDA to become the world’s first and only oral care product to treat both gingivitis and periodontitis (terminal gum disease). According to the CDC, nearly 200 million Americans experience some form of gum inflammation, and until now, oral surgery has been the only viable treatment. The funding will be used to accelerate growth and market penetration of LIVFRESH in the US and Asian markets. Now available, you can learn more about LIVFRESH at www.getlivfresh.com.

Ophthalmology
Livionex is scheduling a Phase 2C study to help its eye-drops become the first non-invasive treatment to improve vision in early-to-moderate cataract patients. Cataracts are the #1 cause of vision loss and are widely considered as an inevitable aspect of aging. According to the National Eye Institute, by 2050, the number of people in the U.S. with cataract problems is expected to double from 24.4 million to about 50 million.

Dermatology
Awarded grants by the National Institutes of Health and the Department of Defense, Livionex has created a transdermal lotion, which could prevent Herpes Simplex Virus eruptions. To put this in perspective, 67% of the global population, or 3.7 billion people, are infected with HSV-1, and 1/4 of those with HSV-1 experience recurrence.

The $4MM Series A represents Livionex’s first acceptance of external funding since the Company’s founding in 2009. Previously self-funded by Amit Goswamy and his partners, Livionex is cash-flow positive and has over 44 patent filings globally to date. The Company looks to IPO in 2021.

About Livionex
Livionex Inc. was founded in 2009 by Stanford and Berkeley alums with the goal of enhancing the quality and longevity of human life. Headquartered in Los Gatos, CA, Livionex develops novel therapies for a variety of age-related chronic diseases affecting billions of people worldwide. The Company’s products are based on its proprietary technology that modulates metal ions that cause oxidative stress and disease. The Company is introducing a new category of treatment for various disorders and diseases associated with metalo lipid protein aggregates, inflammation, and/or bacterial biofilms across ophthalmology, dermatology and oral care. More can be found at www.getlivfresh.com

Filed Under: PR

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Market Analysis

Cloudflare is introducing the concept of the “connectivity cloud”
Robotic Revolution: Japan’s Surging Industrial Robot Market and China’s Dominance
China’s Poaching of Water Technologies from the West: A Serious Concern
Market Scenario of China Banning Exports of Rare Earth Materials and Electric Batteries
Navigating Markets through a 4-Dimensional Research Data Model
A Markov Chain-Based Approach for Forecasting Emerging Technologies: An Extended Analysis
Identifying Resilient Stocks Poised for a Strong Comeback Amidst Economic Recovery

Market Research Media

The Evolution of RSS Feeds: A Media Analyst’s Perspective
AI-Enhanced 4-Dimensional Market Dynamics Analysis: Unveiling Trends, Segmentation, Behavior, and Evolution through Markov Chain Modeling
Autotutoring Market: Personalized Learning and Technological Innovation at the Forefront
Integration of Generative AI and Large Language Models for Enterprises
The Decline of Chinese Media Under Authoritarian Rule: Economic Implications
Algorithmic Bias in Media Recommendation Systems: Unveiling Challenges and Pursuing Fairness
U.S. Federal IT Market Forecast

Secondary Sidebar

Technologies

Apple has announced the winners of the 2023 App Store® Awards
Aalyria and Airbus Collaborate on High-Speed Aerial and Spaceborne Networks
Entrepreneurship Program at Argonne National Laboratory Opens Applications for Startups
Toyota is nearing mass production of solid-state batteries
Cloudflare and Meta Partner to Democratize Access to Llama 2 Open Source Large Language Model (LLM)

Tech Events

Smart City Expo 2023 Reshapes Urban Futures with Unprecedented Participation and Innovation Showcase
SAP SBN User Conference is taking place on October 17-18, 2023 in Oslo, Norway
2023 European Conference on Optical Communication (ECOC) in Glasgow, Scotland, October 2-4, 2023
Bloomberg Technology Summit, October 24t, 2023, London
Imagine 2023, Edge AI Conference, September 27, 2023, Computer History Museum, Mountain View, California

Footer

Recent Posts

  • Silverflow Secures €15 Million Investment to Revolutionize Global Payment Processing
  • Myrror Security, an Israeli company specializing in application security for organizations using open-source packages, has officially launched with $6 million in seed funding
  • Iron Nation Launches Volunteer Emergency Impact Fund to Support Israeli Start-ups Affected by Recent Conflict
  • UnitX, a robotics company specializing in AI vision systems, secures $5 Million
  • UserEvidence, a customer voice platform, secured $9 million in Series A funding
  • Cisco’s $28 Billion Splunk Deal Could Ignite Wave of Software Acquisitions
  • Techstars and The Ohio State University Partner to Boost Software Startups in Columbus
  • Atlys Secures $12M to Revolutionize Visa Processing and Travel Experience
  • Afterparty Raises $5 Million Funding to Revolutionize Creator-Fan Interactions with Afterparty AI
  • Elevator Pitch: BornIntoLuxury.com (Born Into Luxury)

Dossier

Playscript.org: A Comprehensive Repository for Theatre Scripts and Resources
Argil.org: Craft Any Application with Clay-Like Flexibility
Westophobia.com
Preconfiguration.com
Hormuz.net

Press Media Release

We stand by Israel
How to do PR on a budget
Editorial: The Yom Kippur War and its lessons for today
Navigating the New Media Landscape: From Print to Pixels
Analysis 2023

App Coding

Cloudflare Empowers Developers with Full-Stack AI Applications on its Global Network
Building a simple SMS (Short Message Service) application using SQLite and jQuery
Rust for Mobile Apps
Comparison of Design Principles: Mobile Apps vs. Desktop Software
Viral App Ideas to Code for Massive User Engagement

API Coding

Building a Cloudflare-Powered News Republishing API
API Coding Opportunities in Headless Web Publishing
AI-Enhanced API Gateway
Building Powerful APIs for Gaming
Building an API Server to Harness the Power of Large Language Models

Copyright © 2022 3v.org

Technologies, Market Analysis & Market Research and Exclusive Domains

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT